Squarepoint’s Novavax NVAX Stock Holding History
Bought
Maintained
Sold
Other funds holding NVAX
SCM
S
Squarepoint's NVAX Position: Q2 2026 in Review
Squarepoint opened a new position in Novavax (NVAX) in Q2 2026: 133,562 shares worth $1.26M. The stake represents ﹤0.01% of the portfolio and ranks #2721 among its holdings. This is a return to the name: Squarepoint previously reported a position in NVAX as recently as Q2 2025.
Squarepoint first reported a position in NVAX in Q3 2015 and has held it in 27 quarters since. The position peaked at $11.6M in Q2 2022. 268 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.
- Squarepoint held 133,562 shares of Novavax worth $1.26M as of Q2 2026.
- Novavax was a new Squarepoint position in Q2 2026.
- Novavax made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2721 holding.
- Squarepoint first reported a position in Novavax in Q3 2015 and has held it in 27 quarters since.
- Squarepoint's Novavax position peaked at $11.6M in Q2 2022.
- 268 funds tracked by Wall St. Rank held Novavax as of Q2 2026.
Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.